PMV Pharmaceuticals shares are trading higher. The company announced that NEJM publication highlighted the antitumor activity of rezatapopt in advanced solid tumor-types establishing proof-of-concept for p53 reactivation.
PMV Pharmaceuticals, Inc. +8.89% Post
PMV Pharmaceuticals, Inc. PMVP | 1.47 1.47 | +8.89% 0.00% Post |
PMV Pharmaceuticals shares are trading higher. The company announced that NEJM publication highlighted the antitumor activity of rezatapopt in advanced solid tumor-types establishing proof-of-concept for p53 reactivation.
